Daratumumab is an IgG1 humanized mAb that recognizes overexpressed antigen CD38 in MM tumor cells, causing their death through antibody-dependent phagocytosis, complement-dependent cytotoxicity, blocking of CD38, and ADCC [41,42,43,44]. Here, CD38 is linked to neoplasm.